Click here to view the Blue Cross Blue Shield BCBS Massachusetts Medical Policy Updates »…
Capital Blue Cross Medical Policy Updates – December 2022
Click here to view the Capital Blue Cross Medical Policy Updates »
December 2022 Capital Blue Cross Medical Policy Updates:
- Beovu® (brolucizumab-dbll) (Intravitreal)
- Breyanzi® (lisocabtagene Maraleucel) (Intravenous)
- Bronchial Valves
- Clinical Trials and Expanded Access Services
- Corneal Transplant, Endothelial Keratoplasty and Keratoprosthesis
- Deep Brain Stimulation
- Endovascular Grafts for Abdominal Aortic Aneurysms
- Endovascular Grafts for Abdominal Aortic Aneurysms
- Endovascular Stent Grafts for Disorders of the Thoracic Aorta
- Endovascular Stent Grafts for Disorders of the Thoracic Aorta
- Gene Expression Profiling for Melanoma
- General Approach to Genetic Testing
- General Approach to Genetic Testing
- Genetic Testing for Alpha Thalassemia
- Genetic Testing for Li-Fraumeni Syndrome
- Genetic Testing for Lipoprotein (A) Variant (S) as a Decision Aid for Aspirin Treatment
- Home Uterine Ativity Monitoring
- Ilumya® (tildrakizumab-asmn)
- Imfinzi® (durvalumab) (Intravenous)
- Infliximab: Remicade®; Inflectra™; Renflexis™; Avsola™; Infliximab*
- Jemperli® (dostarlimab-gxly) (Intravenous)
- Keytruda® (pembrolizumab) (Intravenous)
- Kymriah® (tisagenlecleucel) (Intravenous)
- Molecular Testing for the Management of Pancreatic Cysts, Barrett Esophagus, and Solid Pancreaticobiliary Lesions
- Multi-Biomarker Disease Activity Blood Test for Rheumatoid Arthritis
- Opdivo® (nivolumab) (Intravenous)
- Orencia® (abatacept)
- Other Therapies of Hyperhidrosis
- Placental/Umbilical Cord Blood as a Source of Stem Cells
- Proteogenomic Testing for Patients with Cancer
- Radiofrequency Ablation of Primary or Metstatic Liver Tumors
- Reduction Mammoplasty for Breast-Related Symptoms
- Spinal Cord and Dorsal Root Ganglion Stimulations
- Spinal Cord and Dorsal Root Ganglion Stimulations
- Spinraza® (nusinersen)
- Stelara® (ustekinumab)
- Steroid-Eluting Sinus Stents
- Taltz® (ixekizumab)
- Technologies for the Evaluation of Skin Lesions Suspected of Malignancy
- Ultomiris® (ravulizumab-cwvz) (Intravenous)
- Yervoy® (ipilimumab) (Intravenous)
- Zynteglo® (betibeglogene autotemcel)
Click here to view the Capital Blue Cross Medical Policy Updates »
Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.
Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!
Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.
Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.
Related Posts
